Ionis Pharmaceuticals, Inc(IONS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IONS Ionis Pharmaceuticals, Inc

已收盘 07-17 16:00:00 EDT

42.17

-0.60

-1.40%

盘后42.17

+0.000.00%

16:20 EDT

最高43.30	最低42.12	成交量199.64万
今开42.90	昨收42.77	日振幅2.75%
总市值67.12亿	流通市值66.52亿	总股本1.59亿
成交额8,477万	换手率1.27%	流通股本1.58亿
市净率14.11	ROE-118.62%	每股收益-3.00
52周最高52.34	52周最低23.95	市盈率-14.07
股息0.00	股息收益率0.00	ROA-10.59%

北京优虎网络科技有限公司

{"stockData":{"symbol":"IONS","market":"US","secType":"STK","nameCN":"Ionis Pharmaceuticals, Inc","latestPrice":42.17,"timestamp":1752782400000,"preClose":42.77,"halted":0,"volume":1996392,"hourTrading":{"tag":"盘后","latestPrice":42.17,"preClose":42.17,"latestTime":"16:20 EDT","volume":75320,"amount":3176244.24,"timestamp":1752783600623},"delay":0,"floatShares":157749379,"shares":159159099,"eps":-2.997331,"marketStatus":"已收盘","change":-0.6,"latestTime":"07-17 16:00:00 EDT","open":42.9,"high":43.295,"low":42.12,"amount":84765233.159496,"amplitude":0.027473,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.997331,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1752825600000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":42.77,"postHourTrading":{"tag":"盘后","latestPrice":42.17,"preClose":42.17,"latestTime":"16:20 EDT","volume":75320,"amount":3176244.24,"timestamp":1752783600623},"volumeRatio":1.093771,"impliedVol":0.4389,"impliedVolPercentile":0.696},"requestUrl":"/m/hq/s/IONS","defaultTab":"news","newsList":[{"id":"2548818467","title":"Ionis Pharmaceuticals, Inc.盘中异动 急速拉升5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2548818467","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548818467?lang=zh_cn&edition=full","pubTime":"2025-07-02 22:02","pubTimestamp":1751464955,"startTime":"0","endTime":"0","summary":"北京时间2025年07月02日22时02分，Ionis Pharmaceuticals, Inc.股票出现波动，股价大幅拉升5.07%。Ionis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.70%。Ionis Pharmaceuticals, Inc.公司简介：Ionis Pharmaceuticals 是利用反义技术发现和开发新型药物的领先开发商。Ionis 于 2024 年获得 FDA 批准，用于治疗罕见的高甘油三酯综合征的 Tryngolza，标志着其首次独立上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070222023597975e76&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070222023597975e76&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"2546230493","title":"Ionis Pharmaceuticals, Inc.盘中异动 大幅拉升5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2546230493","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546230493?lang=zh_cn&edition=full","pubTime":"2025-06-25 03:02","pubTimestamp":1750791744,"startTime":"0","endTime":"0","summary":"北京时间2025年06月25日03时02分，Ionis Pharmaceuticals, Inc.股票出现异动，股价快速上涨5.00%。Ionis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为2.04%。Ionis Pharmaceuticals, Inc.公司简介：Ionis Pharmaceuticals 是利用反义技术发现和开发新型药物的领先开发商。Ionis 于 2024 年获得 FDA 批准，用于治疗罕见的高甘油三酯综合征的 Tryngolza，标志着其首次独立上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250625030224978d39ed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250625030224978d39ed&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"2532098559","title":"Needham：维持Ionis Pharmaceuticals(IONS.US)评级，由买入调整至买入评级, 目标价由60.00美元调整至55.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2532098559","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532098559?lang=zh_cn&edition=full","pubTime":"2025-05-01 03:54","pubTimestamp":1746042840,"startTime":"0","endTime":"0","summary":"Needham：维持Ionis Pharmaceuticals(IONS.US)评级，由买入调整至买入评级, 目标价由60.00美元调整至55.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/01035450065050.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["IONS"],"gpt_icon":0},{"id":"1177766186","title":"异动解读 | 业绩超预期，Ionis Pharmaceuticals盘前大涨6.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=1177766186","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177766186?lang=zh_cn&edition=full","pubTime":"2025-04-30 21:49","pubTimestamp":1746020987,"startTime":"0","endTime":"0","summary":"生物制药公司Ionis Pharmaceuticals, Inc今日盘前股价大涨6.88%，主要受益于公司发布的季度业绩超出市场预期。根据公司公布的财报，截至3月31日的季度，Ionis调整后每股亏损为0.93美元，优于分析师平均预期的1.12美元亏损。值得注意的是，分析师对Ionis Pharmaceuticals保持乐观态度。华尔街分析师给予Ionis Pharmaceuticals未来12个月的目标价中位数为60.00美元，显示出对公司未来发展的信心。然而，投资者也应注意到，该公司今年以来的股价已下跌14.7%，反映出市场对生物科技行业的整体谨慎态度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 业绩超预期，Ionis Pharmaceuticals盘前大涨6.88%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["IONS"],"gpt_icon":0},{"id":"2518070452","title":"Ionis Pharmaceuticals, Inc.盘中异动 大幅下挫5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518070452","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518070452?lang=zh_cn&edition=full","pubTime":"2025-03-11 02:53","pubTimestamp":1741632820,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日02时53分，Ionis Pharmaceuticals, Inc.股票出现波动，股价快速下挫5.00%。Ionis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.60%。Ionis Pharmaceuticals, Inc.公司简介：Ionis Pharmaceuticals 是利用反义技术发现和开发新型药物的领先开发商。Ionis 于 2024 年获得 FDA 批准，用于治疗罕见的高甘油三酯综合征的 Tryngolza，标志着其首次独立上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311025340abf37261&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311025340abf37261&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"2516309676","title":"Ionis Pharmaceuticals, Inc.盘中异动 快速拉升5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516309676","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516309676?lang=zh_cn&edition=full","pubTime":"2025-03-01 04:34","pubTimestamp":1740774847,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日04时34分，Ionis Pharmaceuticals, Inc.股票出现波动，股价大幅拉升5.01%。Ionis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.64%。Ionis Pharmaceuticals, Inc.公司简介：Ionis Pharmaceuticals 是利用反义技术发现和开发新型药物的领先开发商。Ionis 于 2024 年获得 FDA 批准，用于治疗罕见的高甘油三酯综合征的 Tryngolza，标志着其首次独立上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503010434079896c4aa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503010434079896c4aa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"2513270227","title":"Ionis Pharmaceuticals, Inc.2024财年实现净利润-4.54亿美元，同比减少24.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513270227","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513270227?lang=zh_cn&edition=full","pubTime":"2025-02-23 00:00","pubTimestamp":1740240042,"startTime":"0","endTime":"0","summary":"2月23日，Ionis Pharmaceuticals, Inc.公布财报，公告显示公司2024财年净利润为-4.54亿美元，同比减少24.04%；其中营业收入为7.05亿美元，同比减少10.53%，每股基本收益为-3.03美元。机构评级：截至2025年2月23日，当前有22家机构对Ionis Pharmaceuticals, Inc.目标价做出预测，其中目标均价为58.23美元，其中最低目标价为37.00美元，最高目标价为78.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250223000052a24fcc08&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250223000052a24fcc08&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IONS"],"gpt_icon":0},{"id":"2512048389","title":"Ionis Pharmaceuticals, Inc.盘中异动 快速上涨7.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512048389","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512048389?lang=zh_cn&edition=full","pubTime":"2025-02-19 22:31","pubTimestamp":1739975495,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日22时31分，Ionis Pharmaceuticals, Inc.股票出现异动，股价大幅拉升7.20%。Ionis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.15%。其相关个股中，Osr Holdings, Inc.、Aditxt, Inc.、Citius Pharmaceuticals, Inc.涨幅较大，Aditxt, Inc.、Alzamend Neuro, Inc.、Chemomab Therapeutics Ltd较为活跃，换手率分别为206.33%、202.22%、65.58%，振幅较大的相关个股有Osr Holdings, Inc.、Azitra Inc、2Seventy Bio, Inc.，振幅分别为21.86%、11.29%、7.53%。Ionis Pharmaceuticals, Inc.公司简介：Ionis Pharmaceuticals Inc是研发新型药物反义技术的领头研发者。Ionis和阿斯利康将于2024年推出多发性神经病药物Wainua。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219223135abd4fe11&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219223135abd4fe11&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"1151005128","title":"异动解读 | Ionis Pharmaceuticals盘前大涨6.42%,2024Q4业绩超预期引起看涨预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1151005128","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151005128?lang=zh_cn&edition=full","pubTime":"2025-02-19 21:52","pubTimestamp":1739973160,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals, Inc(IONS)今日盘前股价大涨6.42%,引起了市场广泛关注。\n\n令市场看涨的主因是IONS公布了2024年第四季度业绩,财报数据优于预期。具体来看,第四季度销售额达到2.27亿美元,高于分析师预期的1.376亿美元;同时亏损也较预期的1.12美元/股好,为0.66美元/股。\n\n分析师对公司2025年业绩也持乐观态度。IONS管理层预计2025年全年营收将超过6亿美元,而分析师预计营收将达到6.76亿美元。截至2024年底,IONS持有现金及等价物23亿美元,预计2025年底仍将有约17亿美元的现金储备。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["IONS"],"gpt_icon":0},{"id":"1103110364","title":"Ionis制药2024年第四季度GAAP每股亏损$(0.66)优于预期$(1.10)，销售额$2.27亿高于预期$1.376亿","url":"https://stock-news.laohu8.com/highlight/detail?id=1103110364","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103110364?lang=zh_cn&edition=full","pubTime":"2025-02-19 20:07","pubTimestamp":1739966871,"startTime":"0","endTime":"0","summary":"Ionis制药公司报告季度每股亏损$，优于分析师普遍预期的$，提升了40%。与去年同期每股亏损$相比，这一数字大幅下降了1000%。以上内容来自Benzinga Earnings专栏，原文如下：Ionis Pharmaceuticals  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 40 percent. This is a 1000 percent decrease over losses of $ per share from the same period last year.  The company reported quarterly sales of $227.00 million which beat the analyst consensus estimate of $137.60 million by 64.97 percent.  This is a 30.15 percent decrease over sales of $3","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Ionis制药2024年第四季度GAAP每股亏损$(0.66)优于预期$(1.10)，销售额$2.27亿高于预期$1.376亿","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS"],"gpt_icon":0},{"id":"2509255649","title":"Ionis Pharmaceuticals, Inc.盘中异动 快速上涨5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509255649","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509255649?lang=zh_cn&edition=full","pubTime":"2025-02-06 04:21","pubTimestamp":1738786902,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日04时21分，Ionis Pharmaceuticals, Inc.股票出现波动，股价急速上涨5.03%。Ionis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为2.26%。其相关个股中，Immatics N V C/Wts 01/07/2025 、Invivyd, Inc.、Transcode Therapeutics, Inc.涨幅较大，Pasithea Therapeutics Corp.、Transcode Therapeutics, Inc.、Oragenics Inc.较为活跃，换手率分别为4679.47%、2428.06%、1773.50%，振幅较大的相关个股有Oragenics Inc.、Transcode Therapeutics, Inc.、Immatics N V C/Wts 01/07/2025 ，振幅分别为132.24%、99.51%、87.50%。Ionis Pharmaceuticals, Inc.公司简介：Ionis Pharmaceuticals Inc是研发新型药物反义技术的领头研发者。Ionis和阿斯利康将于2024年推出多发性神经病药物Wainua。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206042142abc3c5f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206042142abc3c5f6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"2505049934","title":"Ionis Pharmaceuticals, Inc.盘中异动 快速上涨5.11%报34.16美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2505049934","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505049934?lang=zh_cn&edition=full","pubTime":"2025-01-24 01:11","pubTimestamp":1737652309,"startTime":"0","endTime":"0","summary":"北京时间2025年01月24日01时11分，Ionis Pharmaceuticals, Inc.股票出现异动，股价大幅拉升5.11%。Ionis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.59%。其相关个股中，Dogwood Therapeutics, Inc.、Nutriband Inc C/Wts 、Conduit Pharmaceuticals Inc C/Wts 22/09/2028涨幅较大，Hepion Pharmaceuticals, Inc.、Dogwood Therapeutics, Inc.、Quoin Pharmaceuticals Ltd较为活跃，换手率分别为3681.80%、3081.62%、674.61%，振幅较大的相关个股有Dogwood Therapeutics, Inc.、Nutriband Inc C/Wts 、Conduit Pharmaceuticals Inc C/Wts 22/09/2028，振幅分别为246.43%、65.78%、62.70%。Ionis Pharmaceuticals, Inc.公司简介：Ionis Pharmaceuticals Inc是研发新型药物反义技术的领头研发者。Ionis和阿斯利康将于2024年推出多发性神经病药物Wainua。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501240111499870d898&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501240111499870d898&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"2503982255","title":"加拿大皇家银行：重申Ionis Pharmaceuticals评级，由优于大市调整","url":"https://stock-news.laohu8.com/highlight/detail?id=2503982255","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503982255?lang=zh_cn&edition=full","pubTime":"2025-01-16 10:23","pubTimestamp":1736994221,"startTime":"0","endTime":"0","summary":"加拿大皇家银行：重申Ionis Pharmaceuticals(IONS.US)评级，由优于大市调整至优于大市评级,目标价由70.00美元调整至70.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250116105556a223ac51&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250116105556a223ac51&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IONS","RY"],"gpt_icon":0},{"id":"2503001265","title":"Ionis Pharmaceuticals, Inc.盘中异动 股价大跌5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503001265","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503001265?lang=zh_cn&edition=full","pubTime":"2025-01-15 02:36","pubTimestamp":1736879813,"startTime":"0","endTime":"0","summary":"北京时间2025年01月15日02时36分，Ionis Pharmaceuticals, Inc.股票出现波动，股价快速下跌5.12%。Ionis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.46%。其相关个股中，Eterna Therapeutics Inc.、Seastar Medical Holding Corp C/Wts 28/10/2027 、Jasper Therapeutics Inc C/Wts 24/09/2026 涨幅较大，Eterna Therapeutics Inc.、Phio Pharmaceuticals Corp.、Soligenix, Inc.较为活跃，换手率分别为1035.35%、567.39%、417.28%，振幅较大的相关个股有Eterna Therapeutics Inc.、Matinas Biopharma Holdings, Inc.、Neurosense Therapeutics Ltd C/Wts 10/11/2026 ，振幅分别为170.74%、69.81%、69.33%。Ionis Pharmaceuticals, Inc.公司简介：Ionis Pharmaceuticals Inc是研发新型药物反义技术的领头研发者。Ionis和阿斯利康将于2024年推出多发性神经病药物Wainua。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115023653a221eb4f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115023653a221eb4f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"2503531959","title":"Ionis Pharmaceuticals, Inc.盘中异动 下午盘股价大涨5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503531959","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503531959?lang=zh_cn&edition=full","pubTime":"2025-01-14 02:34","pubTimestamp":1736793291,"startTime":"0","endTime":"0","summary":"北京时间2025年01月14日02时34分，Ionis Pharmaceuticals, Inc.股票出现异动，股价快速上涨5.05%。Ionis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.71%。其相关个股中，Phio Pharmaceuticals Corp.、Salarius Pharmaceuticals, Inc.、Kairos Pharma, Ltd.涨幅较大，Phio Pharmaceuticals Corp.、Salarius Pharmaceuticals, Inc.、Kairos Pharma, Ltd.较为活跃，换手率分别为14072.77%、7500.34%、713.26%，振幅较大的相关个股有Phio Pharmaceuticals Corp.、Salarius Pharmaceuticals, Inc.、Kairos Pharma, Ltd.，振幅分别为336.09%、221.73%、201.86%。Ionis Pharmaceuticals, Inc.公司简介：Ionis Pharmaceuticals Inc是研发新型药物反义技术的领头研发者。Ionis和阿斯利康将于2024年推出多发性神经病药物Wainua。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501140234519864fc1a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501140234519864fc1a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"2492217467","title":"Ionis Pharmaceuticals(IONS.US)旗下罕见病药物Olezarsen获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2492217467","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492217467?lang=zh_cn&edition=full","pubTime":"2024-12-20 15:28","pubTimestamp":1734679712,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，美国食品药品监督管理局已批准Ionis Pharmaceuticals旗下治疗罕见遗传疾病的药物Olezarsen，这是该公司首个全资拥有的药物。Olezarsen被批准作为一种附加治疗，以降低成人患者的甘油三酯水平。受此消息提振，Ionis Pharmaceuticals周四美股盘后涨近7%。Ionis Pharmaceuticals表示，将在投资者电话会议上宣布该药物定价的细节。Kostas Biliouris预估，Ionis Pharmaceuticals旗下FCS治疗药物的销售额最高达3.41亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1227552.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Ionis Pharmaceuticals(IONS.US)旗下罕见病药物Olezarsen获FDA批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"2492464807","title":"Ionis Pharmaceuticals, Inc.盘中异动 股价大涨5.10%报38.48美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492464807","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492464807?lang=zh_cn&edition=full","pubTime":"2024-12-17 02:15","pubTimestamp":1734372915,"startTime":"0","endTime":"0","summary":"北京时间2024年12月17日02时15分，Ionis Pharmaceuticals, Inc.股票出现波动，股价大幅拉升5.10%。Ionis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.85%。Ionis Pharmaceuticals, Inc.公司简介：Ionis Pharmaceuticals Inc是研发新型药物反义技术的领头研发者。Ionis和阿斯利康将于2024年推出多发性神经病药物Wainua。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217021515984c7457&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217021515984c7457&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"2489561482","title":"Ionis Pharmaceuticals, Inc.盘中异动 快速上涨5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2489561482","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489561482?lang=zh_cn&edition=full","pubTime":"2024-12-07 01:24","pubTimestamp":1733505853,"startTime":"0","endTime":"0","summary":"北京时间2024年12月07日01时24分，Ionis Pharmaceuticals, Inc.股票出现异动，股价快速拉升5.03%。Ionis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.29%。Ionis Pharmaceuticals, Inc.公司简介：Ionis Pharmaceuticals Inc是研发新型药物反义技术的领头研发者。Ionis和阿斯利康将于2024年推出多发性神经病药物Wainua。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241207012413ab632914&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241207012413ab632914&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"2486038876","title":"Ionis Pharmaceuticals, Inc.盘中异动 早盘快速拉升5.00%报35.71美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486038876","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486038876?lang=zh_cn&edition=full","pubTime":"2024-11-25 22:44","pubTimestamp":1732545889,"startTime":"0","endTime":"0","summary":"北京时间2024年11月25日22时44分，Ionis Pharmaceuticals, Inc.股票出现波动，股价急速上涨5.00%。Ionis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为1.72%。其相关个股中，Bridgebio Pharma, Inc.、Scholar Rock Holding Corporation、Mural Oncology Plc涨幅较大，Cognition Therapeutics, Inc.、木薯科学、Citius Pharmaceuticals, Inc.较为活跃，换手率分别为92.06%、74.29%、46.90%，振幅较大的相关个股有Kodiak Sciences Inc、Jasper Therapeutics, Inc.、180 Life Sciences Corp C/Wts 07/11/2025，振幅分别为106.46%、106.21%、61.31%。Ionis Pharmaceuticals, Inc.公司简介：Ionis Pharmaceuticals Inc是研发新型药物反义技术的领头研发者。Ionis和阿斯利康将于2024年推出多发性神经病药物Wainua。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112522445098e446ac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112522445098e446ac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"2485428977","title":"Ionis Pharmaceuticals, Inc.盘中异动 临近收盘股价大跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2485428977","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485428977?lang=zh_cn&edition=full","pubTime":"2024-11-22 04:51","pubTimestamp":1732222315,"startTime":"0","endTime":"0","summary":"北京时间2024年11月22日04时51分，Ionis Pharmaceuticals, Inc.股票出现异动，股价大幅下跌5.00%。Ionis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.44%。其相关个股中，Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Briacell Therapeutics Corp.、奥麦罗制药涨幅较大，Biodexa Pharmaceuticals Plc、Conduit Pharmaceuticals Inc.、Tff Pharmaceuticals, Inc.较为活跃，换手率分别为993.23%、551.49%、416.35%，振幅较大的相关个股有Conduit Pharmaceuticals Inc C/Wts 22/09/2028、Rocket Pharmaceuticals Inc C/Wts 02/09/2026 、Biodexa Pharmaceuticals Plc，振幅分别为162.20%、87.47%、84.16%。Ionis Pharmaceuticals, Inc.公司简介：Ionis Pharmaceuticals Inc是研发新型药物反义技术的领头研发者。Ionis和阿斯利康将于2024年推出多发性神经病药物Wainua。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122045156971a7f48&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122045156971a7f48&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IONS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ionispharma.com","stockEarnings":[{"period":"1week","weight":-0.0014},{"period":"1month","weight":0.2137},{"period":"3month","weight":0.506},{"period":"6month","weight":0.3608},{"period":"1year","weight":-0.1419},{"period":"ytd","weight":0.2234}],"compareEarnings":[{"period":"1week","weight":0.0003},{"period":"1month","weight":0.0357},{"period":"3month","weight":0.1858},{"period":"6month","weight":0.0446},{"period":"1year","weight":0.1051},{"period":"ytd","weight":0.0651}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"伊奥尼斯制药公司在反义药物发明和开发上处于行业领先地位，利用新药研发平台，公司研发了大量的一流药品。反义技术在基因学和药物之间打开了一条通道。凭着公司高效多产的药物研发平台，公司可以用反义药物拓展自身及其合作伙伴的药物种类，满足大量的药物需求。公司的策略是做公司最擅长的事--寻找独特的反义药物并开发这些药物，使其成为关键的临床值转折点。公司发明并进行新药早期研究，然后将药物授权给合作伙伴。公司通过把药物交给领先的制药公司进行后期开发来实现药物的最大价值，如Biogen Idec公司、百时美施贵宝公司、 健赞公司、赛诺菲公司、葛兰素史克公司和礼来制药公司。 该公司的旗舰产品 KYNAMRO，正朝着市场上家族性高胆固醇血症患者迈进。 该公司于1989年在美国加州成立。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.026725},{"month":2,"riseRate":0.5,"avgChangeRate":-0.015083},{"month":3,"riseRate":0.3,"avgChangeRate":-0.028033},{"month":4,"riseRate":0.4,"avgChangeRate":0.018094},{"month":5,"riseRate":0.4,"avgChangeRate":-0.049558},{"month":6,"riseRate":0.8,"avgChangeRate":0.059464},{"month":7,"riseRate":0.8,"avgChangeRate":0.040831},{"month":8,"riseRate":0.555556,"avgChangeRate":0.014474},{"month":9,"riseRate":0.444444,"avgChangeRate":-0.002333},{"month":10,"riseRate":0.111111,"avgChangeRate":-0.044503},{"month":11,"riseRate":0.555556,"avgChangeRate":0.09545},{"month":12,"riseRate":0.444444,"avgChangeRate":0.0073}],"exchange":"NASDAQ","name":"Ionis Pharmaceuticals, Inc","nameEN":"Ionis Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ionis Pharmaceuticals, Inc(IONS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Ionis Pharmaceuticals, Inc(IONS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Ionis Pharmaceuticals, Inc,IONS,Ionis Pharmaceuticals, Inc股票,Ionis Pharmaceuticals, Inc股票老虎,Ionis Pharmaceuticals, Inc股票老虎国际,Ionis Pharmaceuticals, Inc行情,Ionis Pharmaceuticals, Inc股票行情,Ionis Pharmaceuticals, Inc股价,Ionis Pharmaceuticals, Inc股市,Ionis Pharmaceuticals, Inc股票价格,Ionis Pharmaceuticals, Inc股票交易,Ionis Pharmaceuticals, Inc股票购买,Ionis Pharmaceuticals, Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ionis Pharmaceuticals, Inc(IONS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Ionis Pharmaceuticals, Inc(IONS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}